

Haematologica  
HAEMATOL/2019/229583  
Version 3

Oral arsenic trioxide ORH-2014 pharmacokinetic and safety profile in patients with advanced hematologic disorders

Farhad Ravandi, Iphigenia Koumenis, Anandhi Johri, Martin Tallman, Gail J. Roboz, Stephen Strickland, Guillermo Garcia-Manero, Gautam Borthakur, Kiran Naqvi, Meghan Meyer, Madhu Pudipeddi, Sirish Nidarmarthy, Kris Vaddi, and Hagop Kantarjian

Disclosures: FR has received research funding and honoraria from Orsenix. All other MD Anderson investigators have no disclosures. IK, KD, AJ, MP, SN, and KV are employees of Orsenix.

Contributions: HK was the initiator of the study and an advisor. KV developed the ORH-2014 formulation. FR, MT, GJR, SS, GG-M, GB, KN, MM, and HK are Principal Investigators who contributed patients to the study, with FR contributing the majority of patients. Orsenix staff conducted the research study including the PK analysis. IK and FR wrote the manuscript.